A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Evolus, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 100 shares of EOLS stock, worth $1,151. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Previous 100 -0.0%
Holding current value
$1,151
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$9.99 - $14.91 $999 - $1,491
100 New
100 $1.4 Million
Q4 2023

Aug 14, 2024

SELL
$7.6 - $10.53 $5,700 - $7,897
-750 Reduced 88.24%
100 $1.05 Million
Q3 2023

Aug 14, 2024

SELL
$7.15 - $10.2 $5,362 - $7,649
-750 Reduced 46.88%
850 $7.77 Million
Q2 2023

Aug 14, 2024

BUY
$7.23 - $10.52 $723 - $1,052
100 Added 6.67%
1,600 $11.6 Million
Q1 2023

Aug 14, 2024

SELL
$7.81 - $11.05 $1,874 - $2,652
-240 Reduced 13.79%
1,500 $12.7 Million
Q4 2022

Aug 14, 2024

BUY
$6.52 - $8.95 $4,172 - $5,728
640 Added 58.18%
1,740 $13.1 Million
Q2 2022

Aug 14, 2024

SELL
$10.22 - $13.94 $15,330 - $20,910
-1,500 Reduced 57.69%
1,100 $12.8 Million
Q1 2022

Aug 14, 2024

BUY
$5.22 - $11.78 $13,050 - $29,450
2,500 Added 2500.0%
2,600 $29.2 Million
Q3 2021

Aug 30, 2024

BUY
$7.36 - $13.67 $20,608 - $38,276
2,800 Added 560.0%
3,300 $25.1 Million
Q2 2021

Aug 30, 2024

BUY
$8.42 - $13.96 $3,368 - $5,584
400 Added 400.0%
500 $6.33 Million
Q1 2021

Aug 30, 2024

SELL
$3.2 - $16.51 $4,800 - $24,765
-1,500 Reduced 75.0%
500 $6.5 Million
Q2 2020

Aug 30, 2024

BUY
$3.53 - $6.17 $3,671 - $6,416
1,040 Added 108.33%
2,000 $10.6 Million
Q1 2020

Aug 30, 2024

BUY
$3.53 - $12.21 $1,412 - $4,884
400 Added 71.43%
960 $3.98 Million
Q2 2019

Aug 30, 2024

BUY
$13.19 - $28.36 $6,067 - $13,045
460 Added 460.0%
560 $8.19 Million

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $646M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.